{"id":"herombopag-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thromboembolic events"}]},"_chembl":{"chemblId":"CHEMBL942","moleculeType":"Small molecule","molecularWeight":"361.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Herombopag works by mimicking the action of endogenous thrombopoietin, a cytokine that regulates megakaryopoiesis and platelet production. By activating the TPO receptor (c-Mpl), it promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet counts. This mechanism is used to treat thrombocytopenia in patients with chronic liver disease or immune thrombocytopenia.","oneSentence":"Herombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocyte progenitor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:02.819Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thrombocytopenia in patients with chronic liver disease"},{"name":"Immune thrombocytopenia (ITP)"}]},"trialDetails":[{"nctId":"NCT07257809","phase":"PHASE2","title":"Herombopag Treated T-DM1 Induced Platelet Reduction","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-10-13","conditions":"Thrombocytopenia","enrollment":56},{"nctId":"NCT07252375","phase":"PHASE2","title":"A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-11-30","conditions":"Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia","enrollment":35},{"nctId":"NCT07243418","phase":"PHASE2","title":"Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-11-30","conditions":"CTIT-Chemotherapy Induced Thrombocytopenia, Breast Cancer","enrollment":72},{"nctId":"NCT06507436","phase":"PHASE3","title":"The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-07-31","conditions":"Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery","enrollment":101},{"nctId":"NCT07198672","phase":"NA","title":"Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag","status":"NOT_YET_RECRUITING","sponsor":"Zhenzhen Liu","startDate":"2025-10-31","conditions":"HER2-positive Breast Cancer","enrollment":45},{"nctId":"NCT06838949","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":"Herombopag","enrollment":80},{"nctId":"NCT06376435","phase":"","title":"A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-04-20","conditions":"Cancer, Therapy-Related","enrollment":500},{"nctId":"NCT06346925","phase":"PHASE1","title":"Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-04","conditions":"Adult Patients With Chronic Primary ITP, Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy","enrollment":18},{"nctId":"NCT06062680","phase":"PHASE1","title":"Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-10","conditions":"Adult Patients With Chronic Primary ITP, Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy","enrollment":15},{"nctId":"NCT06009965","phase":"PHASE4","title":"Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-20","conditions":"Aplastic Anemia, CSA, Drug Therapy","enrollment":210},{"nctId":"NCT05575986","phase":"PHASE4","title":"Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2022-10","conditions":"Malignant Tumors of the Digestive System, Trombocitopenia","enrollment":40},{"nctId":"NCT05252091","phase":"PHASE2","title":"An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2022-02-20","conditions":"Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05160857","phase":"NA","title":"Clinical Study on the Efficacy and Safety of Hetropapa Ethanolamine Tablets in the Treatment of Thrombocytopenia Caused by Concurrent Radiotherapy and Chemotherapy in Cervical Cancer","status":"UNKNOWN","sponsor":"Second Hospital of Shanxi Medical University","startDate":"2021-12-31","conditions":"Tumor Chemotherapy-related Thrombocytopenia","enrollment":30},{"nctId":"NCT03603132","phase":"PHASE1","title":"A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-07-14","conditions":"Immune Thrombocytopenia","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Herombopag tablets","genericName":"Herombopag tablets","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Herombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocyte progenitor cells. Used for Thrombocytopenia in patients with chronic liver disease, Immune thrombocytopenia (ITP).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}